Public advisory

Sanofi-Aventis Canada Inc. recalling certain insulin pens and cartridges

Last updated

Summary

Product
Certain insulin pens and cartridges manufactured by Sanofi-Aventis Canada Inc shipped on specific dates in July and August, 2026
Issue
Health products - Product safety
What to do

If your product is labelled with a lot number listed in the table, contact the place where you obtained the product to determine if your specific unit is affected. Only certain units within these lots are being recalled. If your product is affected, or if you are unsure, do not use it. Return it for a replacement and proper disposal. If you have used an affected product, monitor your blood sugar more closely. If you experience any unusual symptoms or have any other health concerns, consult a healthcare professional.

Distribution
National

Affected products

Name DIN Lot Expiry
Admelog 100 IU/mL – box of 5 cartridges 02469898 5F044A 11/2028
6F007A 12/2028
Admelog SoloSTAR 100 IU/mL – box of 5 pens 02469871 6F755A 01/2029
6F756A 02/2029
6F757A 02/2029
Apidra SoloSTAR 100 IU/mL – box of 5 pens 02294346 6F957A 02/2028
Lantus SoloSTAR 100 IU/mL – box of 5 pens 02294338 6F0565A 10/2028
Toujeo DoubleSTAR 300 IU/mL – 1 pen (sample) 02493373 5F037A 04/2027
Toujeo DoubleSTAR 300 IU/mL – box of 3 pens 02493373 6F055A 09/2027
Toujeo SoloSTAR 300 IU/mL – 1 pen (sample) 02441829 4F284A 03/2027
Toujeo SoloSTAR 300 IU/mL – box of 3 pens 02441829 6F663A 08/2028
Toujeo SoloSTAR 300 IU/mL – box of 5 pens 02441829 6F680A 08/2028
Trurapi 100 IU/mL – box of 5 cartridges 02506564 6F029A 07/2028
6F029B 07/2028
Trurapi SoloSTAR 100 IU/mL – box of 5 pens 02506572 6F387A 06/2028
6F403A 07/2028

Issue

Sanofi-Aventis Canada Inc. is recalling certain insulin pens and cartridges from multiple lots as they may have been frozen during shipping. Insulin products that have been frozen may have reduced effectiveness. Using compromised insulin products may lead to high blood sugar (hyperglycemia).

Only a limited number of units in each lot are being recalled, not the entire lot. The affected units were shipped to approximately 80 pharmacies, clinics and hospitals across Canada on July 13, 14, 15, and August 10, 11, 12, 13, 2026. In total, only 1,043 units are affected, which is less than 1% of the total number of units distributed. Sanofi-Aventis Canada Inc. has informed the specific pharmacies, clinics and hospitals impacted by this recall.

Insulin is used to control high blood sugar in adults and children with diabetes. While unopened product should be kept in a refrigerator at 2°C to 8°C, it should never be frozen. Storage conditions for opened insulin (in use) vary by product. Please refer to the package insert for instructions.

Warning symptoms of high blood sugar include: frequent urination, feeling thirsty, feeling hungry, dry mouth, blurred vision, tiredness or sleepiness, breath that smells fruity or like acetone (nail polish remover), nausea and vomiting. High blood sugar may only be seen by measuring blood sugar levels, and may not display any physical signs. Prolonged or severely high blood sugar may lead to serious health consequences requiring medical treatment, such as confusion, loss of consciousness, seizures, coma, and in rare situations, death.

Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions, and will inform the public if new risks are identified.

What you should do

  • Only a limited number of units within the listed lots are affected by this recall. Do not assume your product is affected solely because the lot number appears in the table.
  • If your product is labelled with a lot number listed on the table, contact the place where you obtained the product to determine if your specific unit is affected.
  • If your product is affected, or if you are unsure, do not use it. Return it to the place where you obtained the product for replacement and proper disposal.
  • If you have used an affected product, monitor your blood sugar more closely. If you experience any unusual symptoms or have any other health concerns, consult a healthcare professional.
  • Contact Sanofi-Aventis Canada Inc. by calling toll-free at 1-800-265-7927 if you have questions about this recall.
  • Report any health product-related side effects or complaints to Health Canada.

Additional information

Details
Original published date:
Alert / recall type
Public advisory
Category
Health products - Biologic or vaccine
Companies

Sanofi-Aventis Canada Inc.
1755 Steeles Avenue West
Toronto, Ontario, M2R 3T4
1-800-265-7927

Published by
Health Canada
Audience
Distribution
National
Recall class
Type I
Identification number
RA-82686
Media and public enquiries

Health Canada
613-957-2983
media@hc-sc.gc.ca

Public Enquiries:
613-957-2991
1-866-225-0709
info@hc-sc.gc.ca

Get notified

Receive emails about new and updated recall and safety alerts.

Subscribe